Self-reported compliance with capecitabine: Findings from a prospective cohort analysis

Oncology

Volumn 80, Issue 1-2, 2011, Pages 29-33

  Winterhalder, Ralph ^a   Hoesli, Pierre ^b   Delmore, Geoffrey ^c   Pederiva, Stefanie ^d   Bressoud, Albéric ^e   Hermann, Frank ^f   Von Moos, Roger ^g  

^a LUZERNER KANTONSSPITAL   (Switzerland)

^b Etablissements Hospitaliers du Nord Vaudois   (Switzerland)

^c Kantonsspital Frauenfeld   (Switzerland)

^d Cantonal Hospital Baden   (Switzerland)

^e Hopital Pourtales Neuchatelois   (Switzerland)

^f Roche Pharma Schweiz AG   (Switzerland)

^g KANTONSSPITAL GRAUBÜNDEN   (Switzerland)

Author keywords

Breast cancer; Capecitabine; Compliance; Gastrointestinal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; IRINOTECAN; NAVELBINE; OXALIPLATIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; COHORT ANALYSIS; COLORECTAL CANCER; DIARRHEA; ESOPHAGUS CANCER; FEMALE; GASTROINTESTINAL TUMOR; HAND FOOT SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; NEUROPATHY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SELF REPORT; STOMACH CANCER; STOMATITIS; VOMITING;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; DIARRHEA; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NAUSEA; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; SELF REPORT; STOMATITIS; VOMITING;

EID: 79956206507     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000328317     Document Type: Article

References (20)

1. O'Neill VJ, et al: Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer 2002; 87: 933-937. (Pubitemid 35305640)
2. Ruddy K, et al: Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59: 56-66.
3. Ziller V, et al: Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 2009; 20: 431-436.
4. Kruk ME, et al: The relation between intermittent dosing and adherence: preliminary insights. Clin Ther 2006; 28: 1989-1995. (Pubitemid 46215746)
5. Midgley R, et al: Capecitabine: have we got the dose right? Nat Clin Pract Oncol 2009; 6: 17-24.
6. Macintosh PW, et al: A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl) 2007; 16: 380-386.
7. Rough A, et al: Questionnaire audit assessing compliance in colon cancer patients taking adjuvant capecitabine (X) as part of the X-ACT trial (abstract 283P). Ann Oncol 2004; 15(suppl 3):iii75.
8. Cramer JA, et al: Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47. (Pubitemid 351160875)
9. Vander Stichele R: Measurement of patient compliance and the interpretation of randomized clinical trials. Eur J Clin Pharmacol 1991; 41: 27-35.
10. Blum JL, et al: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-493. (Pubitemid 29075232)
11. Jasti S, et al: Correction for errors in measuring adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr 2006; 136: 479-483. (Pubitemid 43228305)
12. Waterhouse DM, et al: Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11: 1189-1197. (Pubitemid 23163362)
13. Pullar T, et al: Time to stop counting the tablets? Clin Pharmacol Ther 1989; 46: 163-168. (Pubitemid 19219952)
14. Partridge AH, et al: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol 2010; 28: 2418-2422.
15. Barron TI, et al: Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 2007; 109: 832-839. (Pubitemid 46333524)
16. Smith A, et al: Compliance with drug treatment. Br Med J 1979; 1: 1335-1336. (Pubitemid 9172416)
17. Tebbi CK, et al: Compliance of pediatric and adolescent cancer patients. Cancer 1986; 58: 1179-1184. (Pubitemid 16046957)
18. Lancaster D, et al: Profile of non-compliance in lymphoblastic leukaemia. Arch Dis Child 1997; 76: 365-366. (Pubitemid 27174552)
19. Lash TL, et al: Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 2006; 99: 215-220. (Pubitemid 44268270)
20. Demissie S, et al: Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 2001; 19: 322-328. (Pubitemid 32112842)